IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
MAb, IL-17A, Novartis AIN 457 A7E, D5B II
MAb, interleukin-13, Novartis QAX 576 R3X, R7X, R1B II
mGlu5 receptor antagonist AFQ 056 N4A, N7X, A3F II
neurokinin 1 and 2 antagonist DNK 333 A3G II
oral phosphate binder SBR 759 V3G II
panobinostat LBH 589 L1X9 II
pegmusirudin SPP 200 C6A, B1E II
renin inhibitor SPP 635 C9X II
reverse transcriptase inhibitor IDX 899 J5C3 II
RSV therapy RSV 604, A 60444 J5B5 II
sotrastaurin AEB 071 L4A II
vaccine, HCV epitope-based, Intercell IC41, IC 41, IC 41202 J7A3 II
vaccine, nicotine withdrawal NIC 002, CYT002-NicQb N7B, J7A9 II
vaccine, pseudomonas aeruginosa,
Intercell — J7A9 II
Alzheimer’s disease therapy CAD 106 N7X, N7D9, J7C I
anticancer agent AEE 788 L1X4 I
antiepileptic BGG 492 N3A I
atherosclerosis therapy APP 018, APL 180 C6A I
cancer therapy RAF 265 L1X4 I
COPD therapy QAX 028 R3X I
dovitinib TKI 258, CHIR 258 L1X4 I
drug delivery system, human parathyroid
hormone — M5B9, H4E, V7A I
glaucoma therapy RKI 983 S1E I
glaucoma therapy SAD 448 S1E I
hepatitis C therapy NIM 811, SDZ 811 J5B1 I
hypertension therapy LCI 699 C2A I
hypertension therapy VNP 489 C2A I
MAb, cancer, MorphoSys/Novartis BHQ 880 L1X3 I
MAb, DR5, Novartis LBY 135 L1X3 I
multiple sclerosis therapy BAF 312 N7X I
osteoporosis therapy ATF 936 M5B9 I
PI3K NVP BEZ235, BEZ 235 L1X9 I
PI3K inhibitor BGT 226 L1X4 I
psoriasis therapy AHT 956 D5B I
psoriasis therapy BCT 194 D5A I
RA therapy QAL 964 M1C I
renin inhibitor SPP 1148 C9X I
renin inhibitor SPP 676 C9X I
S1P receptor agonist KRP 203 L4A I
spinal cord injury therapy ATI 355 N7X I
vaccine adjuvant IC31 J7C, L3A9 I
vaccine, cytomegalovirus, Novartis — J7A9 I
vaccine, Group B Streptococcus, Novartis — J7A9 I
vaccine, H pylori, Novartis — J7A9 I
vaccine, HIV infection, Novartis — J7A9, J5C9 I
asthma therapy VAK 694 R3X Preclinical
Bcr-Abl inhibitors, Lilly/Novartis — L1X4 Preclinical
cell cycle inhibitor AT 9311 L1X9 Preclinical
HCV NS3/4A protease inhibitors, Idenix — J5B1 Preclinical
HSP 90 inhibitor HSP 990 L1X9 Preclinical
inflammatory diseases therapy AVP 28225 L4A, M1C Preclinical
mitotic kinesin Eg5 inhibitor BQS 481 L1X9 Preclinical
mitotic kinesin Eg5 inhibitor LCL 161 L1X9 Preclinical
PI3K inhibitor BKM 120 L1X9 Preclinical
renin inhibitor SPP 800 C9X Preclinical
RNA polymerase inhibitor IDX 375 J5B1 Preclinical
SMO inhibitor LDE 225 L1X9 Preclinical
© 2009 IMS Health In cor po rated or its af fil i ates Page 75